{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vision+Loss+Night",
    "query": {
      "condition": "Vision Loss Night"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vision+Loss+Night&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T17:26:41.212Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06349759",
      "title": "Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mesopic Vision",
        "Night Vision Loss"
      ],
      "interventions": [
        {
          "name": "phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocuphire Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-04-01",
      "completion_date": "2026-02-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 25,
      "location_summary": "Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more",
      "locations": [
        {
          "city": "Pheonix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349759"
    },
    {
      "nct_id": "NCT02909985",
      "title": "Visual Activity Evoked by Infrared in Humans After Dark Adaptation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Retinitis Pigmentosa",
        "Congenital Stationary Night Blindness",
        "Colorblindness"
      ],
      "interventions": [
        {
          "name": "Tungsten halogen light with narrow bandpass filters",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-09",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02909985"
    },
    {
      "nct_id": "NCT00500812",
      "title": "A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "Cethrin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2005-02",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500812"
    },
    {
      "nct_id": "NCT05203939",
      "title": "Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "OCU400 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 Med Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 High Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 Second Eye Dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocugen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-01-24",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203939"
    },
    {
      "nct_id": "NCT04123626",
      "title": "A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Autosomal Dominant Retinitis Pigmentosa",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Retinal Dystrophies",
        "Retinal Disease",
        "Retinitis",
        "Vision Tunnel",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "QR-1123",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ProQR Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-10-07",
      "completion_date": "2022-06-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-06",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04123626"
    },
    {
      "nct_id": "NCT01703559",
      "title": "The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Night Vision Complaints",
        "Decrease in Night Vision",
        "Disturbance; Vision, Loss"
      ],
      "interventions": [
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ocuphire Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-09-09",
      "completion_date": "2012-04-30",
      "has_results": false,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703559"
    },
    {
      "nct_id": "NCT03011541",
      "title": "Stem Cell Ophthalmology Treatment Study II",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Disease",
        "Age-Related Macular Degeneration",
        "Retinitis Pigmentosa",
        "Stargardt Disease",
        "Optic Neuropathy",
        "Nonarteritic Ischemic Optic Neuropathy",
        "Optic Atrophy",
        "Optic Nerve Disease",
        "Glaucoma",
        "Leber Hereditary Optic Neuropathy",
        "Blindness",
        "Vision Loss Night",
        "Vision Loss Partial",
        "Vision, Low",
        "Retinopathy",
        "Maculopathy",
        "Macular Degeneration",
        "Retina Atrophy"
      ],
      "interventions": [
        {
          "name": "Arm 1",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "MD Stem Cells",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2016-01",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 2,
      "location_summary": "Westport, Connecticut • Coral Springs, Florida",
      "locations": [
        {
          "city": "Westport",
          "state": "Connecticut"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011541"
    },
    {
      "nct_id": "NCT06961864",
      "title": "Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Visual Snow Syndrome",
        "Migraine",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Visual Adaptation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Assessments and Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Functional Magnetic Resonance Imaging (fMRI)",
          "type": "DEVICE"
        },
        {
          "name": "Magnetic Resonance Imaging (MRS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-04-11",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06961864"
    },
    {
      "nct_id": "NCT04638660",
      "title": "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dim Light Vision Disturbances"
      ],
      "interventions": [
        {
          "name": "Phentolamine Ophthalmic Solution 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Ophthalmic Solution Vehicle (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocuphire Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2020-12-30",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 17,
      "location_summary": "Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pittsburg",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04638660"
    },
    {
      "nct_id": "NCT05085964",
      "title": "An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Usher Syndrome Type 2"
      ],
      "interventions": [
        {
          "name": "RNA antisense oligonucleotide for intravitreal injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-09-16",
      "completion_date": "2022-10-18",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-06-10T17:26:41.212Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05085964"
    }
  ]
}